Sanofi-Aventis Expects Broad Label For Acomplia After FDA Obesity Panel
Executive Summary
Sanofi-Aventis is interpreting the results of FDA's recent Endocrinologic & Metabolic Drugs Advisory committee on obesity drug development as a sign that its obesity/smoking cessation agent Acomplia will be approved with a broad label
You may also be interested in...
Sanofi To Offer Broad Metabolic Syndrome Support Program For Acomplia
Sanofi-Aventis is positioning Acomplia as part of a comprehensive cardio-metabolic disease management program that includes patient and physician support services
Sanofi To Offer Broad Metabolic Syndrome Support Program For Acomplia
Sanofi-Aventis is positioning Acomplia as part of a comprehensive cardio-metabolic disease management program that includes patient and physician support services
Sanofi Feels The Weight Of FDA’s “Approvable” Letter For Rimonabant
FDA is not requesting additional clinical trials for Acomplia's weight loss indication, Sanofi-Aventis said Feb. 24 during its investors meeting in Paris